Takeda Pharmaceutical

Executive Summary

Takeda Pharmaceutical is a global biopharmaceutical leader with a market cap of $57.75B, headquartered in Tokyo, Japan. The company has a diversified portfolio spanning oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies, underpinned by its transformational 2019 acquisition of Shire. Key growth drivers include Entyvio (vedolizumab) for inflammatory bowel disease, Takhzyro (lanadelumab) for hereditary angioedema, and its plasma business. Despite facing patent expiries and debt from the Shire acquisition, Takeda has maintained stable revenues and is focusing on pipeline innovation. The company's R&D strategy emphasizes early-stage assets in oncology, rare diseases, and neuroscience, with a target to deliver multiple new molecular entities by 2030. Takeda's strong commercial execution, global reach, and commitment to R&D position it well for long-term growth, though near-term challenges include generic competition and pricing pressures.

Upcoming Catalysts (preview)

• Q4 2026Entyvio subcutaneous formulation approval in US/EU for ulcerative colitis and Crohn's disease85% success
• H2 2026TAK-279 (oral TYK2 inhibitor) Phase 3 topline data in moderate-to-severe plaque psoriasis70% success
• Q3 2026Takhzyro (lanadelumab) regulatory decision for pediatric hereditary angioedema prophylaxis90% success